ストックスクリーナーアプリを入手
77.00
0.09%
0.16
前日終値:
$76.84
開ける：
$77.2
24時間の取引高:
629.82K
Relative Volume:
0.31
時価総額：
$10.71B
収益：
$105.82M
当期純損益:
$-829.61M
株価収益率:
-11.25
EPS:
-6.8429
ネットキャッシュフロー:
$-548.92M
1週間 パフォーマンス:
+1.37%
1か月 パフォーマンス:
-4.74%
6か月 パフォーマンス:
+9.71%
1年 パフォーマンス:
+100.60%
1日の値動き範囲:
$75.65
$77.99
1週間の範囲:
$74.76
$77.99
52週間の値動き範囲:
$35.22
$88.31
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
77.02 | 10.73B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
550.42 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
829.89 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,014.42 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
139.21 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.10 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Wells Fargo | Overweight |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-12-18 | アップグレード | Goldman | Neutral → Buy |
| 2025-07-30 | 再開されました | Raymond James | Mkt Perform |
| 2025-04-24 | 開始されました | Barclays | Overweight |
| 2025-02-07 | 開始されました | Citigroup | Buy |
| 2025-01-22 | 開始されました | Stifel | Buy |
| 2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-07 | 開始されました | B. Riley Securities | Buy |
| 2023-08-15 | 開始されました | SVB Securities | Outperform |
| 2023-02-17 | 開始されました | BofA Securities | Neutral |
| 2022-12-23 | 繰り返されました | Needham | Buy |
| 2022-12-20 | 開始されました | Truist | Buy |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-01-28 | 開始されました | Goldman | Buy |
| 2021-12-22 | 開始されました | Oppenheimer | Outperform |
| 2021-12-10 | 開始されました | JP Morgan | Overweight |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2021-02-18 | 開始されました | Barclays | Overweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-29 | 開始されました | Goldman | Neutral |
| 2020-07-10 | 開始されました | Raymond James | Strong Buy |
| 2020-05-05 | 開始されました | Mizuho | Buy |
| 2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
| 2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
| 2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-07-31 | 開始されました | Morgan Stanley | Overweight |
| 2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
| 2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
| 2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 繰り返されました | Needham | Buy |
| 2015-11-10 | 繰り返されました | FBR Capital | Outperform |
| 2015-11-09 | 繰り返されました | ROTH Capital | Buy |
| 2015-07-24 | 繰り返されました | MLV & Co | Buy |
| 2014-12-31 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
| 2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
Cytokinetics to Present ACACIA-HCM Hot Line Results and Host Investor Event at ESC Congress 2026 - Quiver Quantitative
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) ... - Caledonian Record
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Yahoo Finance
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock? - Yahoo Finance
Cytokinetics (CYTK) EVP Research & Development Fady Malik Sells 3,500 Shares - GuruFocus
Cytokinetics EVP Fady Ibraham Exercises Stock Options and Sells 3,500 Shares Under Rule 10b5-1 Plan - Kalkine Media
Cytokinetics EVP research & development sells $265,370 in stock By Investing.com - Investing.com Nigeria
Cytokinetics EVP research & development sells $265,370 in stock - Investing.com
Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells $265,370.00 in Stock - MarketBeat
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
symbol__ Stock Quote Price and Forecast - CNN
Will MYQORZO Traction Amid Weaker Q2 2026 Results Change Cytokinetics' (CYTK) Narrative - webull.com
Cytokinetics (NASDAQ:CYTK) Raised to Hold at Wall Street Zen - MarketBeat
H.C. Wainwright reiterates Cytokinetics stock rating on patent suit By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Cytokinetics stock rating on patent suit - Investing.com
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers - Yahoo Finance
Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript - AOL.com
Cytokinetics files patent lawsuit against Bristol-Myers Squibb over heart drug - The Business Journals
Wellington group discloses over 5% Cytokinetics (CYTK) holding for clients - Stock Titan
CYTK Maintained by Barclays -- Price Target Raised to $110 - GuruFocus
CYTK Looks 60.3% Undervalued on GF Value™ Despite Legal Dispute - GuruFocus
CYTK Maintained by JP Morgan -- Price Target Raised to $103 - GuruFocus
JPMorgan Chase & Co. Raises Cytokinetics (NASDAQ:CYTK) Price Target to $103.00 - MarketBeat
Cytokinetics sues Bristol-Myers in patent case (CYTK:NASDAQ) - Seeking Alpha
Form 8K Cytokinetics Inc For: 13 August By Investing.com - Investing.com Nigeria
Cytokinetics files lawsuit seeking patent judgment against Bristol-Myers Squibb - Investing.com South Africa
Cytokinetics Initiates Legal Action Challenging Patent on MYQORZO (Aficamten) - Kalkine Media
PD Small-Cap Value Index Portfolio's Cytokinetics Inc(CYTK) Holding History - GuruFocus
Barclays raises Cytokinetics stock price target on strong Myqorzo sales - Investing.com
Barclays raises Cytokinetics stock price target on strong Myqorzo sales By Investing.com - Investing.com Australia
Cytokinetics, Incorporated $CYTK Shares Purchased by Tema ETFs LLC - MarketBeat
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance
Handelsbanken Fonder AB Grows Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Inc (CYTK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dimensional Fund Advisors LP Has $6.23 Million Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics president & CEO Robert Blum sells $575,700 in shares By Investing.com - Investing.com UK
Cytokinetics Insider Sold Shares Worth $575,700, According to a Recent SEC Filing - moomoo.com
HC Wainwright Raises Earnings Estimates for Cytokinetics - MarketBeat
Cytokinetics, Incorporated (CYTK) Stock forecasts - Yahoo Finance UK
Cytokinetics president & CEO Robert Blum sells $575,700 in shares - Investing.com
Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells $575,700.00 in Stock - MarketBeat
Cytokinetics, Incorporated Revenue Breakdown – NASDAQ:CYTK - TradingView
CYTOKINETICS, INCORPORATED : LEERINK PARTNERS RAISES TARGET PRICE TO $103 FROM $100 - Bitget
CYTOKINETICS, INCORPORATED : TRUIST SECURITIES RAISES TARGET PRICE TO $112 FROM $106 - Bitget
Truist Adjusts Price Target on Cytokinetics to $112 From $106, Maintains Buy Rating - marketscreener.com
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
Cytokinetics Inc (CYTK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Aug 18 '26 |
Sale |
75.82 |
3,500 |
265,370 |
153,902 |
| Blum Robert I | President & CEO |
Aug 10 '26 |
Option Exercise |
10.60 |
7,500 |
79,500 |
385,320 |
| Blum Robert I | President & CEO |
Aug 10 '26 |
Sale |
76.76 |
7,500 |
575,700 |
377,820 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jul 30 '26 |
Option Exercise |
23.26 |
14,000 |
325,640 |
72,555 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jul 30 '26 |
Sale |
79.88 |
14,000 |
1,118,320 |
58,555 |
1.14%
0.28%
大文字化:
|
ボリューム (24 時間):